Top > Search of International Patents > NOVEL ANTI-PAD4 ANTIBODY

NOVEL ANTI-PAD4 ANTIBODY NEW_EN

Foreign code F190009933
File No. (S2018-0142-N0)
Posted date Oct 24, 2019
Country WIPO
International application number 2018JP047871
International publication number WO 2019131769
Date of international filing Dec 26, 2018
Date of international publication Jul 4, 2019
Priority data
  • P2017-249589 (Dec 26, 2017) JP
Title NOVEL ANTI-PAD4 ANTIBODY NEW_EN
Abstract An anti-PAD4 antibody that binds to active PAD4 or an anti-PAD4 antibody that inhibits the function of active PAD4 is achieved. An anti-PAD4 antibody is used which binds to active PAD4. Or, an anti-PAD4 antibody which binds specifically to a peptide formed from the amino acid sequence represented by sequence number 1, or an anti-PAD4 antibody which binds specifically to positions 633-644 of human PAD4 is used. This anti-PAD4 antibody optionally inhibits the citrullination activity of PAD4.
Outline of related art and contending technology BACKGROUND ART
Is PAD4(Peptidylarginine deiminase 4), citrulline arginine protein known as enzymes involved. This citrullinated is, most of the amino acids constituting the protein are highly basic and neutral where an arginine is converted to a reaction for citrulline, protein structure is important for the reaction.
PAD4 (RA) arthritis and rheumatoid arthritis to be involved in the pathology report indicating that there are several. For example, in Non-Patent Document 1, PAD4 with the development of RA gene single nucleotide polymorphisms and the correlation between the reported. Non-Patent Document 2 is, for the diagnosis of RA against the PAD4 antibody was used have been reported. Patent Document 1 is, 4 kinds of anti-PAD4 antibodies to mice by administering the mixture, an attempt to suppress the RA have been described. Is Patent Document 2, an anti-PAD4 antibody that binds to an epitope identified by administering a mouse, can be suppressed or arthritis RA have been described.
PAD4 Is, 'PAD4' and the 'active-inactive PAD4' is present. Ca2 + Is active and to bond, also referred to as Ca2 +-binding PAD4. Combining the non-active type is not Ca2 +, also referred to as the PAD4 Ca2 + non-bonded.
PAD4 And Ca2 + as reported, for example, Patent Document 3 exists. Patent Document 3 is, of rheumatoid arthritis patients and healthy serum amount PAD4, anti-PAD4 antibody is measured using ELISA described attempts. In the embodiment of Patent Document 3, when executing the ELISA, unprocessed serum using the appropriate measurement value cannot be obtained, and processing serum used EDTA an appropriate measurement value is obtained is described. At this time, as a result of the trap Ca2 + to EDTA, anti-PAD4 antibody that reacts with the non-active thought PAD4.
Scope of claims (In Japanese)[請求項1]
 活性型PAD4(Peptidylarginine deiminase 4)に結合する、抗PAD4抗体。

[請求項2]
 活性型PAD4のシトルリン化活性を阻害する、請求項1に記載の抗PAD4抗体。

[請求項3]
 配列番号1で示されるアミノ酸配列からなるペプチド、又はヒトPAD4の633~644位に特異的に結合する、請求項1又は2に記載の抗PAD4抗体。

[請求項4]
 モノクローナル抗体である、請求項1~3いずれかに記載の抗PAD4抗体。

[請求項5]
 抗原結合性抗体断片である、請求項1~4いずれかに記載の抗PAD4抗体。

[請求項6]
 請求項1~5いずれかに記載の抗PAD4抗体をコードする、ポリヌクレオチド又はベクター。

[請求項7]
 請求項1~5いずれかに記載の抗PAD4抗体を含む、PAD4の機能阻害剤。

[請求項8]
 請求項6に記載のポリヌクレオチド又はベクターを含有する細胞を増殖させる工程を含む、抗PAD4抗体の生産方法。

[請求項9]
 配列番号1で示されるアミノ酸配列からなるペプチド。

[請求項10]
 化学修飾ペプチドである、請求項9に記載のペプチド。

[請求項11]
 請求項9又は10に記載のペプチドを含む抗原組成物。

[請求項12]
 請求項9又は10に記載のペプチドで哺乳類又は鳥類を免疫する工程を含む、抗PAD4抗体の生産方法。

[請求項13]
 請求項9又は10に記載のペプチドと、抗PAD4抗体を含む試験サンプルと、を接触させる工程を含む、活性型PAD4に結合する抗体の検出方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NAGOYA CITY UNIVERSITY
  • YOKOHAMA CITY UNIVERSITY
  • Inventor
  • KANAZAWA, Satoshi
  • SATO, Mamoru
  • YAMADA, Michiyuki
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close